Baraclude
Developed to manage chronic hepatitis b infection to alleviate viral replication.
- Category
- Antivirals
- Active ingredient
- Entecavir
- Supply
- Pharmacy
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 0.5mg
Baraclude details
- Condition
- Chronic Hepatitis B
- Therapeutic class
- Hepatitis B Antiviral
- Pharmacological class
- Nucleoside Analogue
- Contraindications
- hypersensitivity to entecavir
- Minor side effects
- headache; fatigue
- Moderate side effects
- dizziness; nausea
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Pharmacist only, dispensed without a prescription
- Manufacturer
- Bristol-Myers Squibb
- Onset Time
- varies
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- drugs affecting renal function
- Pregnancy and breastfeeding
- Pregnancy: use only if clearly necessary. Breastfeeding: not recommended.
Precautions and warnings
risk of lactic acidosis; severe acute exacerbations of hepatitis upon discontinuation; monitor renal function
Serious side effects
lactic acidosis, requires immediate medical attention; severe hepatomegaly with steatosis, requires immediate medical attention
Patient summary
developed to manage chronic hepatitis b infection to alleviate viral replication.
Mechanism of action
Inhibits hepatitis B virus polymerase, which interferes with the viral replication process.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Baraclude
Baraclude is a medication containing the active ingredient Entecavir, utilised for the management of Chronic Hepatitis B. Manufactured by Bristol-Myers Squibb, it is provided as a tablet in a strength of 0.5mg. It functions by inhibiting viral replication, assisting in controlling the virus to help maintain liver health over the long term.
Baraclude availability in Asia
Baraclude comprises a registered presence across 14 markets including Hong Kong, Thailand and Malaysia, with availability also in the Philippines, Indonesia and Taiwan. While the original brand is well-regarded, generic Entecavir is often more affordable for individuals living in areas where consistent medical supply is limited. Given the long-term nature of this condition, this treatment is most effective when used under the guidance of a medical professional.